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Summary
 
Repeated injections of adult mice with recombinant murine TNF prolong the survival of
NZB/W F1 mice, and suppress type I insulin-dependent diabetes mellitus (IDDM) in non-
obese diabetic (NOD) mice. To determine whether repeated TNF injections suppress T cell
function in adult mice, we studied the responses of influenza hemagglutinin-specific T cells de-
rived from T cell receptor (HNT-TCR) transgenic mice. Treatment of adult mice with murine
TNF for 3 wk suppressed a broad range of T cell responses, including proliferation and cyto-
kine production. Furthermore, T cell responses of HNT-TCR transgenic mice also expressing
the human TNF-globin transgene were markedly reduced compared to HNT-TCR single
transgenic littermates, indicating that sustained p55 TNF-R signaling is sufficient to suppress T
cell function in vivo. Using a model of chronic TNF exposure in vitro, we demonstrate that (
 
a
 
)
chronic TNF effects are dose and time dependent, (
 
b
 
) TNF suppresses the responses of both
Th1 and Th2 T helper subsets, (
 
c
 
) the suppressive effects of endogenous TNF produced in T cell
cultures could be reversed with neutralizing monoclonal antibodies to TNF, and (
 
d
 
) prolonged
TNF exposure attenuates T cell receptor signaling. The finding that anti-TNF treatment in
vivo enhances T cell proliferative responses and cytokine production provides evidence for a
novel regulatory effect of TNF on T cells in healthy laboratory mice. These effects are more
pronounced in chronic inflammatory disease. In addition, our data provide a mechanism
through which prolonged TNF exposure suppresses disease in animal models of autoimmunity.
 
O
 
ver the last 10 years, much evidence has accumulated
to implicate tumor necrosis factor alpha (TNF-
 
a
 
) in
the pathogenesis of such autoimmune diseases as rheuma-
toid arthritis (RA)
 
1
 
, multiple sclerosis and type I insulin de-
pendent diabetes mellitus (IDDM). Early experimental ap-
proaches revealed that TNF exerts multiple proinflammatory
and costimulatory effects on a broad range of cell types in
vitro (reviewed in reference 1). The findings that TNF is a
key mediator of cell activation, regulation of MHC class I
and II expression, and the induction of secondary inflam-
matory mediators (1, 2), as well as having direct effector
functions on target organs (3–5), provide further evidence
for its role in disease pathogenesis. That TNF may play a
role in vivo has been supported by more recent studies
demonstrating increased expression of TNF and its recep-
tors at sites of chronic inflammation (reviewed in reference 2),
and the clear beneficial effects of anti-TNF treatment on
the development of collagen-induced arthritis, experimental
autoimmune encephalomyelitis, and experimental allergic
uveitis (6–8). Only a limited number of studies have docu-
mented anti-TNF effects in human disease. Nevertheless,
anti-TNF injections are therapeutic in patients with RA
and chronic inflammatory bowel disease, findings which
are all the more striking given their therapeutic efficacy in
established disease (9, 10).
Paradoxically, data from our own laboratory have dem-
onstrated that repeated injections of adult NZB/W F1
mice with TNF protect mice from the development of lu-
pus-like nephritis and prolong survival (11, 12). Similar
treatment regimens suppress the incidence of spontaneous
type I IDDM in adult NOD mice (13, 14), effects repro-
duced by local overexpression of transgene encoded TNF
in pancreatic islets (15). These results suggest that the out-
come of TNF expression in different disease models may
depend on a number of parameters, including the site of
expression and the duration of TNF exposure. For exam-
 
1
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ple, upregulation of TNF expression at local sites of inflam-
mation may induce effects that are quite different from
those induced by systemic exposure after repeated intraperi-
toneal injections. On the other hand, the acute effects of
TNF may differ from those arising from chronic exposure
to either endogenous or recombinant TNF.
More recent evidence from this laboratory shows that the
timing of TNF exposure is also critical. Repeated injections
of female NOD mice with TNF from birth until 3 wk of age
enhances T and B cell responses to islet cell autoantigens,
and increases the incidence and severity of IDDM (14). Con-
versely, anti-TNF injections over the same time period pre-
vent disease altogether, and abolish T and B cell responses
to autoantigens. These results point to an important role for
TNF in the maturation of autoreactive T lymphocytes. Thus,
whereas TNF may function in some way as a growth factor
for T cells during development, chronic TNF exposure sup-
presses the function of mature T cells in adult mice.
To investigate this further, we have studied how TNF
modulates the functions of T cells from healthy adult TCR
transgenic mice. We have chosen to focus on chronic
rather than short-term TNF effects in vivo and in vitro, in
order to investigate the mechanisms for the disease sup-
pressing effects of repeated TNF injections in adult mice.
The results reported here show that chronic TNF exposure
suppresses the responses of Th1 and Th2 T cells in vitro
and in vivo, by attenuating T cell receptor signaling. Chronic
anti-TNF exposure heightens these same T cell responses
and also increases T cell receptor signaling. These findings
define a novel regulatory role for TNF on T cell responses
in healthy laboratory mice, effects that become more pro-
nounced in chronic inflammatory disease. In addition, the
data indicate that cytokine networks involved in TNF reg-
ulation in vivo will in turn influence the level of T cell
responsiveness.
 
Materials and Methods
 
Mice.
 
BALB/c.McD and B10.D2.McD inbred strains were
obtained from Jackson ImmunoResearch Labs. (West Grove,
PA), and have been maintained for more than 20 yr. HNT-TCR
transgenic mice were generated and characterized as previously
described (16), and backcrossed at least seven generations to
BALB/c and B10.D2 strains. The transgenic TCR is specific for
the influenza hemagglutinin peptide 126-138 presented in the
context of I-A
 
d
 
. Human TNF-globin transgenic lines Tg197 and
Tg3647 were generated as described (17). All transgenic and in-
bred strains were maintained under barrier isolation conditions at
the Stanford University Animal Facility. Single HNT-TCR or
double HNT-TCR 
 
3
 
 human TNF-globin transgenic mice were
studied from 6–14 wk of age.
 
Transgenic T Cells, Chronic TNF Culture and Proliferation As-
says.
 
Transgenic mice were treated for the indicated period and
then killed before stimulation of lymph node and/or spleen T cell
suspensions (5
 
 3 
 
10
 
5
 
 cells/well) with the indicated concentrations
of the influenza hemagglutinin peptide HA 126-138. Axillary,
brachial, inguinal, and popliteal lymph nodes were used in all ex-
periments. For in vitro cultures, peptide-specific T cells were de-
rived from the lymph nodes and spleen of HNT-TCR transgenic
mice, and propagated in complete medium (RPMI 1640, 10%
FCS, 20 mM 
 
l
 
-glutamine, 50 
 
m
 
M 2-mercaptoethanol, 1 mM so-
dium pyruvate, 10 mM Hepes and antibiotics), and 20 U/ml re-
combinant murine IL-2 (a gift of Dr R. L. Coffman, DNAX,
Palo Alto, CA), after repeated cycles of stimulation with 2 
 
m
 
g/ml
peptide plus irradiated (3,000 rad) splenic APC. The HA 126-138
peptide was synthesized as described (18). CD4
 
1
 
 T cells were pu-
rified with specific monoclonal antibodies coupled to magnetic
beads, according to the manufacturer’s instructions (Miltenyi Bio-
tec, Inc., Sunnyvale, CA). For chronic TNF treatment (see Fig.
5), 1–2
 
 3 
 
10
 
6
 
 T cells were stimulated with 2 
 
m
 
g/ml peptide, IL-2,
and 5
 
 3 
 
10
 
6
 
 irradiated splenic APC in the presence or absence of
TNF (or anti-TNF) in a final volume of 2 ml. After 2–3 d, cultures
were supplemented with fresh medium, IL-2, and further addi-
tions of TNF; this was repeated a further 2–3 times. After 10–14 d
of culture, cells were harvested and washed extensively before re-
stimulation of equal numbers of viable control or TNF treated T
cells (10
 
5
 
) with 5
 
 3 
 
10
 
5 
 
fresh splenic APC and antigen. All recall
assays were performed in the absence of exogenous cytokine or
mAb. Proliferation was determined in round-bottomed 96-well
plates in triplicate by [
 
3
 
H]thymidine incorporation during the last
16–18 h of 72-h assays. Medium was supplemented with Neutri-
doma SP (Boehringer Mannheim Corp., Indianapolis, IN) or 1%
autologous mouse serum in place of FCS.
 
Cytokines, Monoclonal Antibodies, and Cytokine Assays.
 
Recom-
binant murine TNF
 
a
 
 was provided by Genentech Inc. (South San
Francisco, CA). Specific activities were as described (14).
TN3.19.12 (hamster IgG1), an mAb specific for murine TNF,
was prepared as described (19). An Ig isotype-matched mAb
(L2.3D9) or purified hamster IgG (Pierce Chem. Co., Rockford,
IL) served as control Ab (control Ig). Murine TNF, anti-TNF or
control antibodies were diluted in PBS and injected i.p. in a final
volume of 100 
 
m
 
l. At the end of treatment, suspensions of lymph
nodes and/or splenocytes were stimulated with 0.5 
 
m
 
g/ml HA
peptide at a density of 7–8
 
 3 
 
10
 
6
 
 cells/ml, in a final volume of 1 ml
in 24-well plates. After prolonged in vitro culture, 2
 
 3 
 
10
 
6
 
 T cells
were stimulated with 5
 
 3 
 
10
 
6
 
 irradiated splenic APC and peptide
as above. Supernatants were harvested at the indicated times and
stored at 
 
2
 
80
 
8
 
C until assayed. Cytokine immunoassays were per-
formed with purified capture and biotinylated detection antibody
pairs (PharMingen, San Diego, CA), and the specific signal deter-
mined from a standard curve of recombinant cytokine on a Wal-
lac fluorometer after sequential incubations with streptavidin-
europium conjugate and enhancement solution (DELFIA Research
Systems, Wallac Inc., Gaithersburg, MD).
 
Flow Cytometric and Ca
 
2
 
1
 
 Flux Analyses.
 
Phycoerythrin-con-
jugated anti-murine CD4 antibodies, FITC-conjugated anti-CD8
(Caltag), and B220 antibodies, biotin-conjugated anti-CD69, anti-
CD44, anti-CD25, and anti-CD45RB (PharMingen), and anti-
V
 
b
 
8.1/8.2/8.3 (F23.1, gift of Dr. S. Webb, The Scripps Re-
search Institute, La Jolla, CA), were used to stain suspensions of
activated T cells or unstimulated lymph node and spleen cell pop-
ulations. Cells were fixed in 1% paraformaldehyde in PBS after
staining, and analyzed on a FACScan
 
Ò
 
 with Lysis II software
(Becton Dickinson and Co., Mountain View, CA).
[Ca
 
2
 
1
 
]i measurements were determined using the Ca
 
2
 
1
 
 depen-
dent variable wavelength indicators fura-2 AM or indo-1 AM
(Molecular Probes Inc., Eugene, OR) as described (20). [Ca
 
2
 
1
 
]i
fluxing determined by FACS
 
Ò
 
 have been described in detail (16,
18). Spectrofluorometric analysis was performed on a Perkin El-
mer LS50 luminescence spectrometer with cells suspended in
PBS, 5% FCS containing 1 mM Ca
 
2
 
1
 
, and Mg
 
2
 
1
 
, with continu-
ous gentle stirring. T cells and APC were mixed and pelleted as 
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described (16). To allow for differences in baseline ratios between
samples, data are expressed as change in (
 
D
 
)
 
 
 
excitation ratios of
fluorescence (335/380 nm) with emission fixed at 505 nm. In both
assays, cells were maintained at 37
 
8
 
C for the duration of the anal-
ysis.
 
Results
 
Prolonged TNF Exposure In Vivo Suppresses T Cell Re-
sponses.
 
To study the effects of TNF on antigen-specific
T cell function in vivo, we used transgenic mice expressing
rearranged T cell receptor 
 
a
 
 and 
 
b
 
 genes. By backcrossing
HNT-TCR transgenic mice at least seven generations to
BALB/c or B10.D2 strains, we could evaluate TNF effects
in two different genetic backgrounds under circumstances
where the TCR, peptide specificity, MHC restriction ele-
ment (I-A
 
d
 
) and the TNF gene itself are identical.
In preliminary experiments, male BALB/c HNT-TCR
transgenic mice were treated with alternate day injections
of PBS, or 1, 3, or 5 
 
m
 
g TNF i.p. 3 wk of treatment with
5 
 
m
 
g TNF led to consistent reductions in body weight of
between 1.5–2 g compared to PBS treated mice; the num-
bers of T cells from pools of axillary, brachial, inguinal, and
popliteal lymph nodes were also reduced (cell number
 
 3
 
10
 
6
 
: PBS 13.6 
 
6
 
 1.6; TNF 9.42 
 
6
 
 0.9, 
 
n
 
 
 
5
 
 3). Doses of 1
or 3 
 
m
 
g, on the other hand, had no effects on either param-
eter, and cell viability was 
 
.
 
95% in all experiments. Ac-
cordingly, the 3 
 
m
 
g dose was chosen for subsequent exper-
iments. Fig. 1 shows a comparison of the responses of
transgenic T cells from pairs of BALB/c transgenic mice
after 3 wk of treatment with PBS or 3 
 
m
 
g TNF. In the first
set of six experiments, we compared the proliferative re-
sponses of T cells derived from lymph node, spleen, or pools
of lymph node and splenic T cells after stimulation with 0.5
 
m
 
g/ml HA peptide (Fig. 1 
 
a
 
). Chronic TNF exposure in
vivo suppressed peptide-specific T cell responses from be-
tween 57–80% compared to PBS-treated cells (mean 
 
6
 
SD: 69 
 
6
 
 8%, 
 
n
 
 
 
5
 
 6), regardless of the magnitude of the
response or the source of T cells, indicating that suppressive
effects are not mediated exclusively by lymph node or
spleen cells. Suppression of responses was observed across a
broad range of peptide concentrations, as shown below (see
Figs. 3 
 
b
 
 and 4 
 
b
 
). However, chronic TNF treatment did
not alter proliferation of lymph node T cells in response to
exogenous IL-2 (Fig. 1 
 
a
 
).
To investigate this further, larger numbers of transgenic
mice were treated with PBS or TNF, and lymph node IL-2
production was determined after stimulation with peptide
in vitro (Fig. 1 
 
b
 
). IL-2 production by T cells chronically ex-
Figure 1. The effects of chronic TNF treatment on peptide-specific re-
sponses of transgenic T cells. 8–12-wk-old male BALB/c HNT-TCR
transgenic mice were injected i.p. with PBS or 3 mg murine TNF on al-
ternate days for 3 wk before study. (a) The proliferative responses of lymph
node (LN), splenic (Spl) or LN 1 Spl pools of T cells from pairs of trans-
genic littermates treated with PBS (shaded bars) or TNF (hatched bars) were
compared after stimulation with 0.5 mg/ml HA peptide (left), or 20 U/ml
recombinant IL-2 (right), as described in Materials and Methods. Data are
expressed as mean cpm 6 SEM from 9 independent experiments. Back-
ground cpm 6 SD in the absence of peptide, which ranged from 889–
2537 cpm, were as follows: PBS, 2167 6 575; TNF, 1992 6 568 (P
.0.1). Significant differences between treatments were observed for re-
sponses to peptide (P ,0.008, paired T test), but not to IL-2 (P .0.2). (b)
7 3 106 lymph node T cells were stimulated with 0.5 mg/ml HA peptide
and culture supernatants harvested at the indicated times. Each data point
represents IL-2 production of transgenic lymph node T cells from one
mouse, as determined by immunoassay. Data are pooled from three inde-
pendent experiments. Differences between PBS and TNF treatments were
statistically significant at 36 and 72 h (P ,0.0005, independent T test).
Table. 1 Comparison of the Phenotype of Lymph Node CD41 Cells from PBS- and TNF-treated Transgenic Mice
In vivo
treatment
Whole lymph 
node CD4
Cell surface marker
CD4 gated population
Vb8 CD69 CD44 CD25 CD45RB
MFL % MFL % MFL % MFL % MFL % RBhi RBlo
PBS 147.9 48.5 103.9 91.1 52.2 12.5 76.4 98.6 168.5 18.0 80.3 19.7
TNF 157.4 47.7 108.4 90.6 53.4 15.7 95.7 99.3 229.8 19.8 80.9 19.1
BALB/c HNT-TCR transgenic mice were treated as described in Fig. 1. After 3 wk of injections, lymph nodes were harvested and cell suspensions
stained with mAb specific for the indicated cell surface marker, before analysis by flow cytometry. Data are expressed both as mean log10 fluorescence
(MFL) and % CD41 cells staining positive, as determined by two-color immunofluorescence. MFL and % data for CD4 expression are shown for
whole lymph node populations. Data are representative of three independant determinations.1576 TNF Suppresses T Cell Responses In Vivo and In Vitro
posed to TNF in vivo was suppressed compared to that of
PBS-treated mice (IL-2 mean pg/ml 6 SD: PBS, 10,324 6
2,715; TNF, 6,139 6 1513, n 5 9). Differences remained
significant 72 h after stimulation with peptide, indicating
that the effects of prolonged TNF exposure in vivo were
not short lived. These data suggested that suppression of
proliferative responses by TNF was due to effects on IL-2
production.
To determine whether repeated TNF injections induced
a T cell surface phenotype distinct from control T cells, a
detailed flow cytometric analysis was undertaken (Table 1).
A comparison of CD41 transgenic T cells from PBS- or
TNF-treated mice revealed no clear phenotype that could
account for the suppressive effects described above. For ex-
ample, chronic TNF had no demonstrable effects on the
proportion of lymph node CD41 T cells, nor were levels of
expression of the transgenic T cell receptor (Vb8), CD69,
CD44, or CD25 downregulated. To the contrary, modest
but consistent increases in the levels of CD44 and CD25
expression (MFL) were observed on CD41 T cells from
TNF-treated mice, although no differences in the percent-
age of cells expressing these activation markers were seen.
In addition, TNF had no apparent effects on T cell differ-
entiation, as far as could be determined by CD45RB ex-
pression (Table 1), or on the proportion of B220 expressing
cells in lymph nodes or spleen (data not shown).
The Effects of Chronic TNF Exposure on Cytokine Production
by Transgenic T Cells. To evaluate the effects of chronic
TNF exposure on T cell function, cytokine production was
studied. BALB/c HNT-TCR transgenic mice were in-
Figure 2. The effects of anti-
TNF treatment on cytokine pro-
duction by transgenic T cells.
B10.D2 (a) or BALB/c (b)
HNT-TCR transgenic mice
were injected i.p. on alternate days
with 100 mg anti-TNF (hatched
bars) or control Ig (shaded bars) for
3 wk (6 mice per treatment
group). Peptide-specific cytokine
production by transgenic T cells
was determined as described for
Table 2. Differences between
treatments were significant only
for B10.D2 HNT-TCR trans-
genic mice (P ,0.0015 for IL-2,
and P ,0.05 for IFN-g, inde-
pendent T test).
Table 2. Effects of TNF Injections In Vivo on Cytokine Production In Vitro
Chronic
exposure
in vivo to
36 h 72 h
IL-2 IFN-g IL-4 IL-10
BALB/c
PBS (n 5 9) 10324 6 2715 2507 6 1757 421 6 228 552 6 221
TNF (n 5 9)* 6139 6 1513 1277 6 684 254 6 127 203 6 79
B10.D2
PBS (n 5 3) 2081 6 1378 265 6 66 15 6 3 109 6 40
TNF (n 5 3) 2133 6 1096 199 6 49 19 6 3 82 6 7
Groups of BALB/c or B10.D2 HNT-TCR transgenic mice were treated as described for Fig. 1. After 3 wk of treatment, mice were killed before
stimulation of 7 3 106 lymph node and splenic lymphocytes with 0.5 mg/ml HA peptide. Supernatants were harvested at the indicated times, and
peptide-specific cytokine production (mean pg/ml 6 SD) determined by immunoassay.
*Differences in cytokine production between PBS and TNF treatment were significant for BALB/c HNT-TCR (P ,0.0005 for IL-2 and IL-10,
P ,0.035 for IL-4 and IFN-g), but not for B10.D2 HNT-TCR transgenic mice (P .0.1).1577 Cope et al.
jected i.p. with PBS or TNF as before, and lymph node
T cells from these mice were stimulated in vitro with 0.5
mg/ml HA peptide. The production of IL-2, IFN-g, IL-4,
and IL-10 by transgenic T cells were all suppressed by
chronic TNF treatment in vivo to z50% of levels pro-
duced by control cells (Table 2, top). Using the same treat-
ment regimen, the effects of chronic TNF were then tested
in B10.D2 mice. Surprisingly, TNF treatment had no sig-
nificant effects on cytokine production by lymph node T cells
derived from HNT-TCR transgenic mice crossed to the
B10.D2 strain (Table 2, bottom). One possible explanation
for these findings was that T cells from B10.D2 mice were
suppressed by endogenously expressed TNF, a notion con-
sistent with the finding that activated T cells from the
B10.D2 strain produce more TNF than cells from BALB/c
mice after prolonged culture in vitro (data not shown). To
test this, groups of transgenic littermates were treated with
either 100 mg anti-TNF or control Ig i.p. on alternate days
for 3 wk, before studying peptide-specific cytokine pro-
duction. A comparison of B10.D2 and BALB/c HNT-
TCR transgenic mice revealed that the pattern of responses
was different to that observed for TNF treatment (Fig. 2);
anti-TNF injections enhanced significantly peptide-specific
IL-2 and IFN-g production by transgenic T cells from
B10.D2 mice (Fig. 2 a), while little or no effect on peptide
specific responses was observed in BALB/c T cells (Fig. 2 b).
Differences for IL-4 and IL-10, which are produced at low
levels by B10.D2 transgenic T cells, were not significant.
These results indicated that in strains of healthy laboratory
mice such as B10.D2, endogenous TNF is expressed at lev-
els that suppress T cell cytokine responses.
To determine how rapidly the suppressive effects of en-
dogenous TNF could be reversed in vivo in B10.D2 mice,
pairs of transgenic littermates were injected with anti-TNF
or control Ig, and proliferative responses to peptide deter-
mined after different periods of time. In 7 out of 9 pairs,
T cells derived from anti-TNF–treated mice exhibited signif-
icantly increased proliferative responses compared to con-
trols over a treatment period ranging from 4 d to 5 wk (Fig.
3 a). Increased responses were observed after only two in-
jections of 200 mg anti-TNF, the higher dose being used in
an attempt to achieve saturating levels of mAb over this
shorter time period. In a separate experiment, equal num-
bers of purified CD41 T cells from anti-TNF or control
Ig–treated mice were stimulated with increasing concentra-
tions of peptide and fresh splenic APC derived from non-
transgenic, untreated mice (Fig. 3 b). Increased responses
after anti-TNF treatment were observed as before, over a
wide range of peptide concentrations, while responses to
Con A were unimpaired (see Fig 3 legend). These results
suggest that suppression of T cell function by TNF in vivo
is not due exclusively to effects on accessory cells in vivo.
Nor can they be explained by alterations in numbers of
CD41 cells in lymph nodes by anti-TNF treatment.
The Effects of Sustained p55 TNF-R Signaling In Vivo on T
Cell Responses. Transgenic mice expressing human TNF-
globin transgenes overexpress human TNF and develop spon-
taneous inflammatory arthritis (17). Since human TNF binds
to murine p55 but not p75 TNF-R (21), sustained signals
transduced through murine p55 TNF-R by human TNF
are implicated in this model of chronic inflammation. By
breeding mice to express both TCR and human TNF-
globin transgenes, we investigated the effects of chronic
human TNF exposure on T cell function in mice with
chronic inflammatory disease, and determined whether per-
sistent p55 TNF-R signaling was sufficient to induce sup-
pressive effects in vivo.
The results from these studies are shown in Fig. 4. Fig. 4 a
shows that proliferative responses to peptide of purified
CD41 cells from BALB/c or B10.D2 HNT-TCR 3 hu-
man TNF-globin double transgenic mice were suppressed
Figure 3. Kinetics of the proliferative responses of transgenic T cells af-
ter anti-TNF injections. (a) Pairs of B10.D2 HNT-TCR transgenic litter-
mates were treated i.p. on alternate days with 6–18 injections of anti-
TNF or control Ig (100 mg/injection); mice injected for shorter periods
(2–4 injections) received 200 mg antibody per injection. After the indi-
cated number of injections, mice were killed and transgenic T cells stimu-
lated in vitro with 0.5 mg/ml HA peptide, as described for Fig. 1. *Differ-
ences between treatments were significant (P ,0.02, independent T test).
(b) Mice were injected with anti-TNF or control Ig for 4 wk. At the end
of the treatment period, 105 purified lymph node/splenic CD41 T cells
were stimulated in vitro with increasing concentrations of HA peptide
and 5 3 105 fresh irradiated splenic APC from non-transgenic, untreated
B10.D2 mice. Data represent mean cpm 6 SEM in 72-h proliferation as-
says. Con A responses in a representative experiment were as follows:
control Ig, 38483 6 1784, anti-TNF, 36457 6 5288 cpm 6 SEM.1578 TNF Suppresses T Cell Responses In Vivo and In Vitro
compared to responses of TCR single transgenic litter-
mates. Further analysis revealed that the responses of T cells
from BALB/c double transgenic mice could be reduced by
<95% compared to single transgenic littermates across a
broad range of peptide concentrations (Fig. 4 b). This raised
the possibility that in the human TNF-globin transgene
high expressing line (Tg197), which develops severe arthri-
tis from 4–6 wk of age, T cell function could be suppressed
by the disease rather than specifically to TNF overexpres-
sion. To address this, we studied B10.D2 TCR transgenic
mice crossed to line Tg3647, which expresses human TNF
at lower levels (Kollias et al., unpublished data). Since these
mice develop arthritis over a 2-wk period from 10–12 wk
of age, we were able to study the responses of T cells from
double transgenic arthritic mice with cells from double
transgenic mice before the onset of arthritis, and compare
these with single TCR transgenic mice. T cells from dou-
ble transgenic arthritic mice had lower proliferative re-
sponses than non-arthritic animals, which in turn had lower
responses than HNT-TCR single transgenic mice (Fig. 4 c).
Responses to Con A, however, were unimpaired. A similar
pattern was reflected in IFN-g production, with the high-
est IFN-g production observed upon stimulation of T cells
from HNT-TCR single transgenic mice, and the lowest in
double transgenic arthritic littermates (Fig. 4 d). These data
demonstrate that sustained signaling through murine p55
TNF-R is sufficient to initiate T cell suppression, effects
detectable before clinical signs of inflammatory disease de-
velop.
Studies of Chronic TNF Effects on Activated T Cells In Vitro.
We developed an in vitro model to define in more detail
the phenotype of chronic TNF treated T cells, and to in-
vestigate the mechanisms for these suppressive effects. As
outlined in Fig. 5, this model allowed a detailed compari-
son of activated T cells cultured under conventional condi-
tions, with T cells repeatedly exposed to TNF (or anti-TNF)
in a manner analogous to the in vivo studies described above.
A comparison of the data shown above with experiments
reported previously (22), suggested that the effects of short
and long-term TNF exposure were fundamentally differ-
ent. Accordingly, this notion was tested in vitro by com-
paring the responses of T cells to TNF for different periods
of time. Stimulation of transgenic BALB/c splenocytes
with increasing concentrations of TNF alone had negligible
effects in 72-h proliferation assays. The addition of subopti-
mal concentrations of Con A revealed that TNF signifi-
Figure 5. In vitro model for studying chronic TNF effects. HNT-
TCR transgenic T cells derived from lymph node and/or spleen were
stimulated with splenic APC, 2 mg/ml HA 126-138 and 20 U/ml IL-2 in
the presence or absence of repeated additions of murine TNF or anti-
TNF for up to 14 d, as described in Materials and Methods. All rechal-
lenge assays were performed after extensive washing using equal numbers
of T cells, fresh, irradiated, non-transgenic splenic APC and HA peptide,
in the absence of exogenous TNF or antibody.
Figure 4. Responses of HNT-TCR transgenic T cells from mice ex-
pressing human TNF globin transgenes. (a) Human TNF-globin trans-
genic mice (line Tg197) were crossed to HNT-TCR transgenic mice and
backcrossed 3 generations to BALB/c or B10.D2. At 6–8 wk of age, the
responses to 0.5 mg/ml HA 126-138 of purified CD41 T cells from
HNT-TCR single and HNT-TCR 3 TNF-globin double transgenic lit-
termates were compared in 72-h proliferation assays; (b) 5 3 105 lymph node
T cells from 8-wk-old BALB/c HNT-TCR single or HNT-TCR 3
Tg197 double transgenic littermates were stimulated with increasing con-
centrations of HA 126-138 and proliferative responses determined as for
a; (c and d) human TNF-globin transgenic line Tg3647 was crossed to
B10.D2 HNT-TCR transgenic mice. F1 mice derived from this cross
were monitored for arthritis development. From these litters, pairs of sin-
gle HNT-TCR transgenic mice were studied for T cell proliferative re-
sponses (c) as described for (b) above, and for IFN-g production in re-
sponse to 0.5 mg/ml HA peptide (d), and the responses compared with
those observed for arthritic or non-arthritic HNT-TCR 3 TNF-globin
double transgenic mice. In representative experiments, Con A responses
(mean cpm 6 SD) were as follows: HNT-TCR single transgenic mice,
48513 6 7728; HNT-TCR 3 human TNF-globin double transgenic
mice, 51677 6 10806 (n 5 2 per group).1579 Cope et al.
cantly enhanced the proliferative responses over this time
period (Fig. 6 a). In contrast, repeated exposure of BALB/c
transgenic T cells to similar concentrations of TNF for up
to 12 d led to marked suppression of responses after restim-
ulation with HA peptide and fresh splenic APC (Fig. 6 b,
left). Suppressive effects were dose dependent; between 1
and 10 ng/ml TNF appeared sufficient to suppress T cell
responses. Exposure for at least 4 d was required, but no
further suppression was observed by continuing TNF treat-
ment for more than 12 d through subsequent cycles of
stimulation (data not shown).
Consistent with these findings, prolonged exposure of
transgenic T cells to 10 ng/ml TNF suppressed IL-2 pro-
duction on rechallenge with antigen and APC (Fig. 6 b,
right). Lymph node transgenic T cells from BALB/c mice
were then stimulated with peptide in the presence of re-
peated additions of anti-TNF, control Ig or medium alone.
After 12 d in culture, rechallenge responses to HA peptide
of anti-TNF–treated T cells were found to be enhanced
when compared to control cultures with respect to both
T cell proliferation (Fig. 6 c, left) and IL-2 production 36 h
after peptide stimulation (Fig. 6 c, right). As before, prolifer-
ation to exogenous IL-2 did not differ between treatments
(data not shown). These data indicated that levels of TNF
produced in cultures of transgenic T cells are sufficient to
suppress T cell responses in vitro.
To exclude the possibility that these results were due to
the cytotoxic effects of TNF on T cells, control and TNF-
treated cells were evaluated for viability and total cell num-
ber at the end of the culture period. In nine representative
experiments, viability of T cells, determined by Trypan
blue exclusion, was no different in medium (54.7 6 10.4%)
and TNF-treated cultures (59.4 6 10.6%), the proportion
of dead cells being due to residual irradiated splenic APC.
Furthermore, chronic TNF treatment had no effect on cell
numbers at the end of the stimulation period (medium,
5.83 6 4.1 3 106; TNF, 5.96 6 4.7 3 106 [n 5 33]). Sen-
sitive assays reflecting cell viability, such as 51Cr release, vi-
tal dye assays using tetrazolium salts, as well as staining with
propidium iodide, all failed to demonstrate that chronic
TNF-treated cells were more prone to cell death than cells
from control cultures (data not shown). The finding that
IL-2 or Con A responses of T cells were not suppressed by
chronic TNF exposure (Fig. 1, and data not shown), is
consistent with these observations. Anti-TNF mAb were not
cytotoxic in culture. In fact, anti-TNF treatment increased
T cell numbers to a small extent by the end of the culture
period.
Prolonged TNF Exposure In Vitro Suppresses Th1 and Th2
Cell Subsets. HNT-TCR transgenic T cells derived from
BALB/c and B10.D2 genetic backgrounds have different
cytokine profiles (16), despite the fact that the TNF gene,
the TCR-a and TCR-b chains, antigenic peptide, and the
MHC class II restriction element (I-Ad) are identical. These
differences are most apparent when peptide-stimulated
transgenic T cells become terminally differentiated after cul-
ture in vitro (Cope, A. and R. Liblau, unpublished data).
Specifically, transgenic T cells from BALB/c mice have
characteristics of the Th2 phenotype, while B10.D2 T cells
are Th1-like. We therefore evaluated the effects of TNF or
anti-TNF on the profile of cytokines produced by T cells
from both strains after one cycle of stimulation in vitro.
The results pooled from four experiments are shown for
medium versus TNF (Fig. 7 a), and for control Ig versus
anti-TNF (Fig. 7 b). As expected, BALB/c T cells pro-
duced significant levels of IL-4 and IL-10. B10.D2 T cells
Figure 6. The effects of TNF on T cell responses in vitro are depen-
dent on the exposure period. (a) Acute TNF exposure. Fresh BALB/c
splenocytes (5 3 105/well) were stimulated for 72 h with the indicated
concentrations of TNF, in the presence or absence of suboptimal concen-
trations of Con A (50 ng/ml). Proliferative responses (mean cpm 6 SEM)
were determined as described in Materials and Methods. (b) Chronic
TNF exposure. BALB/c HNT-TCR transgenic lymph node/splenic T
cells were stimulated with HA 126-138 and IL-2 in the presence or ab-
sence of repeated additions of the indicated concentrations of TNF, as de-
scribed in Fig. 5. After 12 d of culture, cells were washed before restimu-
lation with 0.5 mg/ml HA peptide and fresh splenic APC. Data represent
proliferative responses (mean cpm 6 SEM) obtained in 72 h rechallenge
assays (left), or IL-2 production 36 h after restimulation with peptide (4 in-
dependent experiments shown; right panel). (c) Chronic TNF blockade.
Transgenic T cells were stimulated as for b above in the presence of re-
peated additions of 10 mg/ml anti-TNF, control Ig or medium alone.
Proliferative responses and IL-2 production were determined as described
for b. Data from four independent experiments are shown.1580 TNF Suppresses T Cell Responses In Vivo and In Vitro
produced IFN-g, while levels of IL-4 and IL-10 were low
or undetectable. Chronic TNF exposure profoundly sup-
pressed the production of all cytokines after stimulation
with peptide. Suppression was most striking for cytokines
produced at the highest levels. Even for cytokines pro-
duced at much lower levels, prolonged TNF exposure sig-
nificantly reduced levels of IFN-g and IL-4 produced by
BALB/c and B10.D2 T cells, respectively (Fig. 7 a). In a
comparison of control Ig and anti-TNF–treated T cells,
significant increases in peptide-specific cytokine produc-
tion were observed after anti-TNF treatment in cultures of
both BALB/c and B10.D2 T cells. Together, these data in-
dicate that the effects of exogenous and endogenous TNF
on the function of helper T cells are not selective, but sup-
press both Th1 or Th2 cell subsets.
Chronic TNF Exposure In Vitro Attenuates T Cell Receptor
Signaling. The data described above demonstrated that
prolonged TNF exposure suppresses a broad range of T cell
responses after stimulation with antigenic peptide. These
experiments compared T cell responses 24 h or more after
peptide stimulation. To address the mechanism for chronic
TNF effects, we wished to investigate whether chronic
TNF modulates earlier events of the TCR signaling cas-
cade. Accordingly, we evaluated the effects of prolonged
TNF or anti-TNF exposure on mobilization of intracellu-
lar Ca21 stores in transgenic T cells after restimulation with
HA peptide. In preliminary experiments, transgenic T cells
were stimulated with splenic APC loaded with 60 mg/ml
HA peptide. No significant differences in Ca21 fluxing was
observed in T cells after chronic TNF treatment. However,
when lower concentrations of peptide were used (10 mg/ml),
different responses were observed. Fig. 8 shows representa-
tive data from Ca21 fluxing experiments of BALB/c trans-
Figure 7. TNF suppresses the responses of Th1 and Th2 transgenic
T cells. Transgenic T cells derived from BALB/c (closed symbols) and
B10.D2 (open symbols) HNT-TCR transgenic mice were stimulated as de-
scribed for Fig. 6 in the presence or absence of repeated additions of me-
dium alone or 10 ng/ml TNF (a), or 10 mg/ml anti-TNF or control Ig
(b). Cytokine production (mean pg/ml) was determined by immunoassay
at 36 h for IFN-g (circles), and 72 h for IL-4 (triangles) and IL-10 (dia-
monds) after restimulation with 0.5 mg/ml HA peptide. Data from four in-
dependent comparisons are shown. Statistically significant differences be-
tween treatments are shown (paired T test).
Figure 8. The effects of chronic TNF exposure on intracellular Ca21
mobilization. BALB/c HNT-TCR transgenic T cells were stimulated in
vitro with HA 126-138 peptide in the presence or absence of repeated ad-
ditions of 10 ng/ml TNF (a), or 10 mg/ml anti-TNF or control Ig (b).
Calcium fluxing was determined after 11 d in culture by spectrofluoro-
metric (a), or by flow cytometric analyses (b), after restimulation of T cells
with fresh splenic APC loaded with 10 mg/ml peptide. Data are shown
for T cell/splenic APC cells in the presence or absence of 10 mg/ml HA
peptide, and expressed as D Ca21 flux (335/380 nm) ratio (a: medium,
solid line, TNF, dotted line) as a function of time (min), or the % indo-1–posi-
tive, FITC-negative cells (b) fluxing during the first 60 s of analysis after
peptide stimulation.1581 Cope et al.
genic T cells determined by spectrofluorometric analysis (Fig.
8 a), and by flow cytometry (Fig. 8 b). In Fig. 8 a, spectro-
fluorometric analysis revealed that both the kinetics and
amplitude of peptide specific Ca21 mobilization in acti-
vated BALB/c transgenic T cells is altered by chronic TNF
treatment; peak D Ca21 ratios of 0.432 were observed after
43.89 s of analysis for control cultures, compared to a re-
sponse of 0.228 at 58.52 s for TNF-treated cells. Experi-
ments performed with B10.D2 cells revealed similar results;
control versus TNF, a ratio of 0.137 after 54.34 s versus
0.075 after 87.78 s. These differences represented reduc-
tions in amplitude of .60% for BALB/c and z50% for
B10.D2, as a consequence of chronic TNF exposure. De-
spite these differences, TNF-treated cells were still capable
of sustaining Ca21 mobilization throughout the test period.
To evaluate the effects of endogenous TNF, we investi-
gated the effects of anti-TNF treatment on calcium fluxing
at the single cell level by flow cytometry. By excluding
FITC positive and indo-1 negative cells, fluxing of the
CD41 population could be studied specifically. In the ab-
sence of peptide, no appreciable calcium fluxing could be
detected for either anti-TNF or control Ig-treated T cells
(Fig. 8 b). In the presence of HA peptide, maximal detect-
able levels of [Ca21]i could be observed in both control Ig-
and anti-TNF–treated cells. However, the proportion of
fluxing cells was lower after control Ig treatment (36.9%),
compared to anti-TNF (60.1%) during the first 60 s of
analysis, patterns reproduced in cultures of B10.D2 trans-
genic T cells (data not shown). These data demonstrate that
TNF induces qualitative and quantitative changes in TCR
signaling events such that TNF suppresses, and neutralizing
endogenous TNF enhances mobilization of intracellular
Ca21 stores, and provides biochemical evidence to explain
how TNF may suppress T cell function in vivo and in
vitro.
Discussion
Until recently, TNF has been recognized almost exclu-
sively as the prototypic inflammatory mediator, exhibiting
an extensive array of proinflammatory and costimulatory
effects on multiple cell targets. The physiological effects of
endogenous TNF in the absence of acute inflammation in
the adult, on the other hand, are not clearly documented.
We initiated the studies described above to investigate the
mechanisms by which repeated TNF injections suppress
disease in animal models of autoimmunity. Our approach
focused on examining the effects of chronic TNF exposure
in vivo and in vitro on peptide specific T cell function, us-
ing treatment regimens known to protect adult NOD mice
from IDDM, and NZB/W F1 mice from lupus nephritis
(13, 11). We chose to study HNT-TCR transgenic mice
since T cells specific for an influenza hemagglutinin peptide
become autoreactive on the B10.D2 genetic background
when crossed to mice expressing this hemagglutinin in the
pancreatic islets (16). Consistent with our working hypoth-
esis, chronic TNF suppressed a broad range of T cell re-
sponses. Unexpectedly, blocking TNF activity in healthy
mice with anti-TNF injections led to increased T cell pro-
liferation and cytokine production by transgenic T cells,
findings reproduced in an in vitro model. These observa-
tions provide evidence that endogenous physiological levels
of TNF modulate the state of responsiveness of T cells to
subsequent challenge with antigen.
Our studies revealed unexpected differences in peptide-
specific responses between BALB/c and B10.D2 inbred
strains, even though the TNF gene, the antigen, TCR, and
MHC restriction element are identical. Responses from
BALB/c HNT-TCR transgenic mice were suppressed by
TNF injections, but not modified by anti-TNF, while the
reverse was found for T cells derived from the B10.D2
strain. The mechanisms for these differences are under in-
vestigation. Both strains have the same H-2d MHC haplo-
type and thus share TNF coding and regulatory sequences
encoded within the class III region. Consistent with this,
BALB/c and B10.D2 HNT-TCR transgenic mice produce
similar levels of TNF in vitro when assayed up to 72 h after
stimulation with peptide. However, TNF production by
B10.D2 transgenic T cells was increased compared to
BALB/c T cells when membrane TNF expression was ex-
amined 6 d or more after peptide stimulation by flow cy-
tometry (Cope, A., unpublished data). These findings raise
the possibility that in cultures of BALB/c transgenic T cells
there exist factors capable of downregulating TNF expres-
sion that are deficient in B10.D2 cultures. These same fac-
tors may be involved in regulating chronic TNF expression
in vivo, and provide a further example of how the genetic
background can influence cytokine expression or respon-
siveness (23). Cytokines such as IL-4 and IL-10, which are
produced at significantly higher levels by BALB/c HNT-
TCR transgenic T cells compared to B10.D2 T cells in
vitro and in vivo (Table 2, Fig. 7, and reference 16), are
particularly good candidate cytokines since they are known
to suppress TNF expression (24, 25).
These data provide indirect evidence for differential reg-
ulation by cytokine networks, in which regulatory cyto-
kines such as IL-4, IL-10, and perhaps TGF-b influence
TNF expression in vivo and in vitro. The outcome is de-
termined in part by the genetic background of the mouse
strain under investigation. A role for IL-10 as a regulator of
chronic TNF expression in vivo has been proposed re-
cently. Thus, anti–IL-10 mAb treatment substantially de-
lays the onset of autoimmunity in NZB/W F1 mice, while
continuous IL-10 injections accelerated disease onset (26).
In these experiments, the effects of anti–IL-10 could be re-
versed with concomitant administration of anti-TNF mAb,
demonstrating an important role for TNF in downregulat-
ing the disease process. Consistent with this, Zhou et al. (27)
demonstrated greatly accelerated lymphadenopathy and au-
toantibody production in C57BL/6-lpr/lpr.p55 TNF-R-/-
mice compared to C57BL/6-lpr/lpr control animals. These
data demonstrate that by perturbing cytokine networks, the
function of autoreactive lymphocytes can be altered in such
a way as to drastically influence the disease process.
Systemic IL-10 therapy can delay the onset and reduce the
incidence of IDDM in NOD mice (28). In contrast, target-1582 TNF Suppresses T Cell Responses In Vivo and In Vitro
ing overexpression of this cytokine to pancreatic islets in-
duces peri-islet inflammation in BALB/c Ins-IL-10 mice,
and islet cell destruction leading to IDDM in both NOD
and congenic B10.H2g7 background strains (29, 30). Al-
though IL-10 has effects on multiple cell types, one possible
explanation for these findings is that local overexpression of
IL-10 suppresses TNF expression and the suppressive ef-
fects of endogenous TNF exposure on autoreactive T cells
in the islets, thereby enhancing islet cell antigen specific T
cell responses. If this were so, one would predict that block-
ing TNF production by other means should aggravate au-
toimmunity in NOD mice also. Indeed, repeated injections
of adult female NOD mice with anti-TNF significantly in-
crease the incidence and severity of diabetes compared to
control animals (Cope, A.P., and H.O. McDevitt, unpub-
lished data), findings in keeping with previous data from our
laboratory (31); cytokine production in vitro by spleno-
cytes from these anti-TNF–treated mice was also dramati-
cally increased upon stimulation with a panel of islet cell
autoantigens. These data provide key evidence that endog-
enous expression of TNF in 8–20-wk-old NOD mice is suf-
ficient to partially suppress autoreactive T cell responses in
vivo. Flavell and colleagues have reported similar findings
in RIP-TNF transgenic NOD mice (15). Since chronic
TNF effects do not appear to discriminate between Th1
and Th2 effector cells, we propose that repeated TNF in-
jections suppress Th1 responses in adult NOD mice, and
Th2 responses in adult NZB/W F1 mice to an extent suffi-
cient to suppress disease activity.
The responses of T cells to TNF are critically dependent
on the duration of exposure, as well as the state of activa-
tion of the responding cells. In addition to the data pre-
sented here, several other characteristics of chronic TNF ex-
posure are worthy of note. Our findings are not exclusive
to transgenic T cells. For example, an extensive analysis of
PPD-specific T cells chronically exposed to TNF has dem-
onstrated both dose and time dependent effects identical to
those seen in HNT-TCR transgenic T cells. Indeed, previ-
ous reports indicate that chronic TNF influences the func-
tion of human T cells in a similar fashion (32). The data
presented here argue against, but do not completely rule
out the possibility that one mechanism by which chronic
TNF suppresses T cell function is through its effects on
APC function, as suggested previously (33). However, the
data in Fig. 3 b and results found using cultures of T cell
hybridomas in the absence of APC, show that TNF sup-
pressed antigen- or anti-CD3–induced responses with equal
efficiency. Thus, defects in T cell priming by TNF-treated
dendritic cells would appear to be insufficient to account
for our findings.
This in vitro model has provided important clues as to
the mechanisms for TNF suppression. Prolonged TNF ex-
posure does not downmodulate the T cell receptor/CD3
complex. Nor does it suppress responses to exogenous IL-2,
indicating that IL-2R signaling is intact, and raising the
possibility that chronic TNF may target the T cell receptor
signaling pathway. Although some of these characteristics
are shared by cells that are clonally anergic (34), these find-
ings, together with the observation that chronic TNF can
suppress a broad range of T cell responses, suggested partial
rather than complete uncoupling of early signaling events
within T cells.
Intracellular Ca21 mobilization is attenuated by chronic
TNF exposure. Peak levels achieved were reduced and de-
layed by chronic TNF, and the percentage of cells attaining
the maximal response was also reduced. Since expression of
the TCR/CD3 complex is unchanged, these data provide
biochemical evidence that prolonged TNF exposure de-
presses intracellular signaling in T cells. The effects on
TCR signaling are similar to those seen in T cells activated
with altered peptide ligands (35), but are distinct from
those seen in lymphocytes made anergic by high dose ago-
nistic peptide (36), or by IL-10 (37). Under the latter cir-
cumstances, Ca21 mobilization remains intact. The TCR
may be one of several cell surface receptors whose signaling
pathway is influenced by TNF. For example, TNF has been
shown to induce insulin resistance by desensitizing insulin
receptor signaling via inhibition of tyrosine kinase activity,
effects also induced through p55 TNF-R (38). The precise
mechanisms through which TNF attenuates TCR signaling
require further investigation.
In summary, these studies provide an explanation for the
suppressive effects of TNF in animal models of autoimmu-
nity. In addition, they define a novel physiological role for
TNF in the regulation of T cell function in healthy mice.
By attenuating TCR signaling pathways, prolonged expo-
sure to endogenous or exogenous TNF suppresses the re-
sponses of T cells to subsequent challenge with antigen, ef-
fects which can be rapidly and dramatically reversed with
anti-TNF.
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